Clinical trials: Inflammatory Bowel Disease, Ulcerative Colitis Type
- Condition Inflammatory Bowel Disease, Ulcerative Colitis Type
- Funder type Industry (pharma, biotech, devices)
Colitis, Ulcerative
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
- Trial name
- NCT06176560
- Testing
- Mesalazine
- Volunteers
- 376 people
- Sponsor
- Faes Farma, S.A.
Colitis, Ulcerative, Crohn Disease
A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate how long participants with moderate-to-severe Crohn's Disease (CD) and Ulcerative Colitis (UC) continue treatment with guselkumab in a real-world setting.
- Trial name
- GALILEO (NCT07848737)
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag, S.A.
Ulcerative Colitis
HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
A study with an 8 week open label phase study followed by a year long placebo controlled maintenance phase in subjects with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy…
- Trial name
- NATRUL-4 (NCT01882764)
- Testing
- HMPL-004
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Hutchison Medipharma Limited
Inflammatory Bowel Diseases, Blau Syndrome
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single…
- Conditions
- Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT06206811
- Testing
- OD-07656
- Where
- Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Odyssey Therapeutics, Inc.
Active Ulcerative Colitis
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121).
- Trial name
- NCT07665723
- Testing
- Afimkibart, Caffeine, Warfarin
- Where
- 18 sites in United States, Belgium and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Inflammatory Bowel Diseases, Crohns Disease
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Vedolizumab is a medicine that helps to reduce sensitivity and pain in the digestive system for participants with UC or CD. In this study, adults with UC or CD will be treated with vedolizumab according to their clinic's standard…
- Conditions
- Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative
- Trial name
- NCT04989907
- Where
- 6 sites in Switzerland
- Volunteers
- 92 people
- Sponsor
- Takeda
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Ulcerative Colitis
Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients with Moderate to…
- Trial name
- TOP2 (NCT02888379)
- Testing
- TOP1288
- Where
- 28 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 77 people
- Sponsor
- Topivert Pharma Ltd
Ulcerative Colitis
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies…
- Trial name
- NCT05177835
- Testing
- ABX464
- Where
- 46 sites in Austria, Belgium and 12 more
- Volunteers
- 203 people
- Sponsor
- Abivax S.A.
Ulcerative Colitis
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
This is a Phase I dose-escalation study of MDX-1100. patients with ulcerative colitis will be enrolled into one of four dose cohorts, to receive of MDX-1100 at 0.3, 1.0, 3.0 or 10mg/kg.
- Trial name
- NCT00295282
- Testing
- MDX-1100 (anti-CXCL10 human monoclonal antibody)
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with ulcerative colitis (UC) who were exposed to ozanimod during pregnancy; the second is…
- Trial name
- NCT06126835
- Testing
- Ozanimod, Conventional therapy, Advanced therapy
- Where
- United States
- Volunteers
- 2,828 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis
Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
The study has been designed as a randomised, parallel-group, double-blind, 2 arm study of the comparative efficacy, safety and immunogenicity of AVT16 and Entyvio in male and female subjects with moderate to severe active…
- Trial name
- NCT06570772
- Testing
- AVT16, Vedolizumab
- Where
- 100 sites in Argentina, Bulgaria and 9 more
- Volunteers
- 301 people
- Sponsor
- Alvotech Swiss AG
Colitis, Ulcerative
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
- Trial name
- NCT05076175
- Testing
- Ozanimod
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Active Ulcerative Colitis
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
To demonstrate that import Mesalazine (Asacol®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (reduction of UC-DAI score)in patients with active ulcerative colitis (UC) treated for 8…
- Trial name
- NCT01257386
- Testing
- Asacol®, Mesalazine
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Tillotts Pharma AG
Healthy Men and Subjects With Ulcerative Colitis
A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis
The objectives of this study are to evaluate the safety and tolerability of a single intravenous (IV) or subcutaneous (SC) dose of KHK4083 in Japanese or White healthy men in a placebo-controlled, single-blind comparative study…
- Trial name
- NCT02985593
- Testing
- KHK4083
- Where
- Japan
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Ulcerative Colitis, Crohn's Disease
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD).
- Trial name
- NCT04738942
- Testing
- Vedolizumab
- Where
- 20 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and…
- Trial name
- SELECTION (NCT02914522)
- Testing
- Filgotinib, PTM filgotinib
- Where
- 343 sites in United States, Argentina and 38 more
- Volunteers
- 1,351 people
- Sponsor
- Gilead Sciences
Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT06052059
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 476 sites in United States, Argentina and 43 more
- Volunteers
- 1,109 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis
This is a Phase 2, randomized, double-blind, multicenter, parallel, placebo controlled study. Approximately 120 eligible patients with mild-to-moderate active ulcerative colitis will be randomized to double blind treatment of…
- Trial name
- NCT01612039
- Testing
- ASP3291
- Volunteers
- 112 people
- Sponsor
- Telsar Pharma Inc.
Colitis, Ulcerative
Combined Nutritional Therapies for the Treatment of Ulcerative Colitis
Ulcerative colitis (UC) is an entity of complex etiology where environmental, genetic and intestinal microflora-related factors trigger and perpetuate a chronic inflammation of the gastrointestinal tract.
- Trial name
- NCT03444311
- Testing
- A: 1 dosis, B: 2 dosis
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- AB Biotics, SA